542 related articles for article (PubMed ID: 33407619)
41. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation.
Matsuzaki T; Tatsuki I; Otani M; Akiyama M; Ozawa E; Miuma S; Miyaaki H; Taura N; Hayashi T; Okudaira S; Takatsuki M; Isomoto H; Takeshima F; Eguchi S; Nakao K
J Gastroenterol Hepatol; 2013 Jul; 28(7):1217-22. PubMed ID: 23432697
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of HBV serological markers in treatment-naïve HBV mono-infected patients and HBV-HIV co-infected patients.
Jiang B; Su R; Ren D; Zheng X; Cao Y; Mi Y; Wang F; Ma P
Virus Res; 2020 Dec; 290():198117. PubMed ID: 32800804
[TBL] [Abstract][Full Text] [Related]
43. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ
Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753
[TBL] [Abstract][Full Text] [Related]
44. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
[TBL] [Abstract][Full Text] [Related]
45. Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load--down-regulated transcription of PgRNA has limited impact.
Malmström S; Larsson SB; Hannoun C; Lindh M
PLoS One; 2012; 7(7):e36349. PubMed ID: 22911677
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks.
Wang X; Wang Z; Chi X; Wu R; Jin Q; Xu H; Gao X; Yu L; Chen Y; Shang J; Liu L; Zhang S; Jiang Y; Zhang M; Tong Q; Zhang L; Tan Y; Ma A; Dang S; Xu B; Jin Z; Li J; Li X; Lu F; Niu J
Int J Infect Dis; 2020 Oct; 99():171-178. PubMed ID: 32721532
[TBL] [Abstract][Full Text] [Related]
47. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
[TBL] [Abstract][Full Text] [Related]
48. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Wursthorn K; Lutgehetmann M; Dandri M; Volz T; Buggisch P; Zollner B; Longerich T; Schirmacher P; Metzler F; Zankel M; Fischer C; Currie G; Brosgart C; Petersen J
Hepatology; 2006 Sep; 44(3):675-84. PubMed ID: 16941693
[TBL] [Abstract][Full Text] [Related]
49. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
50. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
[TBL] [Abstract][Full Text] [Related]
51. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
52. Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.
Huang Q; Zhou B; Cai D; Zong Y; Wu Y; Liu S; Mercier A; Guo H; Hou J; Colonno R; Sun J
Hepatology; 2021 Jan; 73(1):41-52. PubMed ID: 32189364
[TBL] [Abstract][Full Text] [Related]
53. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
[TBL] [Abstract][Full Text] [Related]
54. Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis.
Zhang ZQ; Wang YB; Lu W; Liu DP; Shi BS; Zhang XN; Huang D; Li XF; Zhou XL; Ding RR
Ann Lab Med; 2019 Jan; 39(1):67-75. PubMed ID: 30215232
[TBL] [Abstract][Full Text] [Related]
55. Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline.
Arends P; Rijckborst V; Zondervan PE; Buster E; Cakaloglu Y; Ferenci P; Tabak F; Akarca US; Simon K; Sonneveld MJ; Hansen BE; Janssen HL
J Viral Hepat; 2014 Dec; 21(12):897-904. PubMed ID: 24444353
[TBL] [Abstract][Full Text] [Related]
56. Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients.
Lu HY; Zhuang LW; Yu YY; Si CW
J Viral Hepat; 2010 Mar; 17 Suppl 1():59-65. PubMed ID: 20586935
[TBL] [Abstract][Full Text] [Related]
57. Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B.
Beudeker BJ; Groothuismink ZM; de Man RA; Janssen H; van der Eijk AA; Boonstra A; Sonneveld MJ
Antivir Ther; 2020; 25(4):217-222. PubMed ID: 32744512
[TBL] [Abstract][Full Text] [Related]
58. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
[TBL] [Abstract][Full Text] [Related]
59. Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients.
Chen S; Jia J; Gao Y; Li H; Fang M; Feng H; Guan W; Ji J; Gao Z; Gao C
Clin Chim Acta; 2018 Nov; 486():237-244. PubMed ID: 30025756
[TBL] [Abstract][Full Text] [Related]
60. Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B.
Zhang ZQ; Zhang XN; Lu W; Wang YB; Weng QC; Feng YL
BMC Gastroenterol; 2017 Dec; 17(1):140. PubMed ID: 29202690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
